

# Clive Ballard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7191909/publications.pdf>

Version: 2024-02-01

517  
papers

51,445  
citations

2427

97  
h-index

1857

209  
g-index

563  
all docs

563  
docs citations

563  
times ranked

46768  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, The, 2020, 396, 413-446.	13.7	4,658
2	Dementia prevention, intervention, and care. Lancet, The, 2017, 390, 2673-2734.	13.7	4,228
3	Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry, the, 2020, 7, 547-560.	7.4	4,086
4	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
5	Alzheimer's disease. Lancet, The, 2011, 377, 1019-1031.	13.7	2,051
6	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
7	Vascular cognitive impairment. Lancet Neurology, The, 2003, 2, 89-98.	10.2	1,130
8	Putting brain training to the test. Nature, 2010, 465, 775-778.	27.8	875
9	Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, The, 2014, 383, 533-540.	13.7	756
10	Cognitive decline in Parkinson disease. Nature Reviews Neurology, 2017, 13, 217-231.	10.1	705
11	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
12	The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, The, 2009, 8, 151-157.	10.2	512
13	Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ: British Medical Journal, 2011, 343, d4065-d4065.	2.3	461
14	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 403-411.	13.7	444
15	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurology, The, 2012, 11, 697-707.	10.2	432
16	Depression in Parkinson disease—epidemiology, mechanisms and management. Nature Reviews Neurology, 2012, 8, 35-47.	10.1	431
17	Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ: British Medical Journal, 2006, 332, 756-761.	2.3	424
18	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurology, The, 2009, 8, 613-618.	10.2	420

#	ARTICLE	IF	CITATIONS
19	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	30.5	391
20	Incidence and Prediction of Falls in Dementia: A Prospective Study in Older People. <i>PLoS ONE</i> , 2009, 4, e5521.	2.5	372
21	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.1	365
22	Management of agitation and aggression associated with Alzheimer disease. <i>Nature Reviews Neurology</i> , 2009, 5, 245-255.	10.1	336
23	Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 779-794.	2.6	336
24	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 528-536.	2.7	321
25	Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 553-558.	2.2	315
26	Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. <i>Annals of Neurology</i> , 2005, 58, 773-776.	5.3	312
27	Cholinesterases: Roles in the Brain During Health and Disease. <i>Current Alzheimer Research</i> , 2005, 2, 307-318.	1.4	303
28	Management of behavioral problems in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2010, 22, 346-372.	1.0	295
29	Donepezil for the Treatment of Agitation in Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1382-1392.	27.0	292
30	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013, 9, 602-608.	0.8	292
31	Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 75, 651-659.	2.9	288
32	Assessment and treatment of pain in people with dementia. <i>Nature Reviews Neurology</i> , 2012, 8, 264-274.	10.1	270
33	Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. <i>BMJ: British Medical Journal</i> , 2005, 330, 874.	2.3	261
34	Neuroleptic drugs in dementia: benefits and harm. <i>Nature Reviews Neuroscience</i> , 2006, 7, 492-500.	10.2	257
35	Towards defining the neuropathological substrates of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2004, 226, 75-80.	0.6	252
36	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	10.1	252

#	ARTICLE	IF	CITATIONS
37	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 440-449.	3.7	240
38	Drug repositioning for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 833-846.	46.4	239
39	Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia. <i>Journal of Neurochemistry</i> , 1999, 73, 1590-1597.	3.9	231
40	Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 341-348.	2.2	225
41	A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer's Disease. <i>primary care companion for CNS disorders</i> , The, 2013, 15, .	0.6	221
42	Prevalence and Severity of Gait Disorders in Alzheimer's and Non-Alzheimer's Dementias. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1681-1687.	2.6	214
43	Non-pharmacological interventions in dementia. <i>Advances in Psychiatric Treatment</i> , 2004, 10, 171-177.	0.5	212
44	Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e37410.	2.5	201
45	Prospective Follow-Up Study Between 3 and 15 Months After Stroke. <i>Stroke</i> , 2003, 34, 2440-2444.	2.0	194
46	Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. <i>Lancet</i> , The, 1998, 351, 1032-1033.	13.7	192
47	CSF amyloid- $\beta$ and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1080-1086.	1.9	190
48	Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 160-165.	1.9	187
49	Hypertension is a potential risk factor for vascular dementia: systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 661-669.	2.7	184
50	A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial). <i>PLoS Medicine</i> , 2008, 5, e76.	8.4	183
51	Parkinson Disease With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 295-297.	1.3	183
52	Dementia in Down's syndrome. <i>Lancet Neurology</i> , The, 2016, 15, 622-636.	10.2	180
53	Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. <i>European Journal of Pharmacology</i> , 2000, 393, 215-222.	3.5	172
54	A comparison of $^{99m}\text{Tc}$ -HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 615-622.	6.4	172

#	ARTICLE	IF	CITATIONS
55	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018, 141, 582-595.	7.6	172
56	Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2000, 48, 868-876.	5.3	171
57	Altered neurogenesis in Alzheimer's disease. <i>Journal of Psychosomatic Research</i> , 2006, 61, 311-316.	2.6	170
58	Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 445-452.	1.5	170
59	Is physical activity a potential preventive factor for vascular dementia? A systematic review. <i>Aging and Mental Health</i> , 2010, 14, 386-395.	2.8	167
60	The prognosis of dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2017, 16, 390-398.	10.2	159
61	Endogenous neurogenesis in the human brain following cerebral infarction. <i>Regenerative Medicine</i> , 2007, 2, 69-74.	1.7	157
62	Quality of Life for People With Dementia Living in Residential and Nursing Home Care: The Impact of Performance on Activities of Daily Living, Behavioral and Psychological Symptoms, Language Skills, and Psychotropic Drugs. <i>International Psychogeriatrics</i> , 2001, 13, 93-106.	1.0	155
63	Improving quality of life for people with dementia in care homes: making psychosocial interventions work. <i>British Journal of Psychiatry</i> , 2012, 201, 344-351.	2.8	147
64	Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002500.	8.4	147
65	Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. <i>International Psychogeriatrics</i> , 2019, 31, 83-90.	1.0	146
66	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2012, 379, 528-536.	13.7	144
67	Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology. <i>Neurobiology of Disease</i> , 2012, 47, 155-162.	4.4	144
68	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in <sc>L</sc>ewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	4.1	144
69	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 823-834.	1.2	144
70	Efficacy of Memantine for Agitation in Alzheimer's™s Dementia: A Randomised Double-Blind Placebo Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e35185.	2.5	144
71	The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 990-997.	2.5	143
72	The Pattern of Cognitive Performance in CADASIL: A Monogenic Condition Leading to Subcortical Ischemic Vascular Dementia. <i>American Journal of Psychiatry</i> , 2005, 162, 2078-2085.	7.2	141

#	ARTICLE	IF	CITATIONS
73	Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. <i>International Psychogeriatrics</i> , 2021, 33, 505-514.	1.0	135
74	A 1-Year Follow-Up Study of Behavioral and Psychological Symptoms in Dementia Among People in Care Environments. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 631-636.	2.2	135
75	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. <i>International Psychogeriatrics</i> , 2014, 26, 1083-1098.	1.0	134
76	The Response of Agitated Behavior to Pain Management in Persons with Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 708-717.	1.2	132
77	Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. <i>Lancet Neurology</i> , The, 2018, 17, 213-222.	10.2	131
78	Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy-Confirmed Dementia With Lewy Bodies. <i>American Journal of Psychiatry</i> , 2004, 161, 843-849.	7.2	130
79	An extract of <i>Salvia (sage)</i> with anticholinesterase properties improves memory and attention in healthy older volunteers. <i>Psychopharmacology</i> , 2008, 198, 127-139.	3.1	129
80	A Double-Blind Placebo-Controlled Randomized Trial of <i>Melissa officinalis</i> Oil and Donepezil for the Treatment of Agitation in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 158-164.	1.5	129
81	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 812-817.	2.7	126
82	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 35-43.	2.4	126
83	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, 1149-1158.	0.8	126
84	A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 114-119.	2.2	125
85	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	10.2	124
86	Dementia with Lewy bodies. <i>Seminars in Clinical Neuropsychiatry</i> , 2003, 8, 46-57.	1.9	124
87	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 130.	7.4	121
88	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	10.1	121
89	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 371-377.	2.7	119
90	White Matter Hyperintensities Are Associated With Impairment of Memory, Attention, and Global Cognitive Performance in Older Stroke Patients. <i>Stroke</i> , 2004, 35, 1270-1275.	2.0	118

#	ARTICLE	IF	CITATIONS
91	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 164.	9.0	113
92	Dementia care mapping as a research tool for measuring quality of life in care settings: psychometric properties. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 1064-1070.	2.7	108
93	Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program. <i>American Journal of Psychiatry</i> , 2016, 173, 252-262.	7.2	108
94	The disconnect between evidence and practice: a systematic review of person-centred interventions and training manuals for care home staff working with people with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 797-807.	2.7	105
95	The Prevalence, Assessment and Associations of Falls in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 97-103.	1.5	103
96	Management of Neuropsychiatric Symptoms in People with Dementia. <i>CNS Drugs</i> , 2010, 24, 1.	5.9	102
97	Guidelines for the management of agitation in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 714-717.	2.7	101
98	Identification of Novel $\beta$ -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	3.3	99
99	Elevation in Late-Life Depression of Intercellular Adhesion Molecule-1 Expression in the Dorsolateral Prefrontal Cortex. <i>American Journal of Psychiatry</i> , 2000, 157, 1682-1684.	7.2	98
100	Agitation and aggression in people with Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2013, 26, 252-259.	6.3	98
101	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020, 16, 661-673.	10.1	97
102	Autonomic Function Is Impaired in Elderly Stroke Survivors. <i>Stroke</i> , 2005, 36, 1026-1030.	2.0	96
103	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 2836-2844.	3.1	94
104	Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. <i>Neurobiology of Aging</i> , 2007, 28, 1664-1669.	3.1	93
105	Neuropsychiatric symptoms in dementia: Importance and treatment considerations. <i>International Review of Psychiatry</i> , 2008, 20, 396-404.	2.8	89
106	Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. <i>Current Opinion in Psychiatry</i> , 2009, 22, 532-540.	6.3	87
107	Regulation of attention and response to therapy in dementia by butyrylcholinesterase. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 231-239.	5.7	85
108	Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. <i>Brain</i> , 2006, 129, 1780-1788.	7.6	84

#	ARTICLE	IF	CITATIONS
109	Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2020, 143, 2895-2903.	7.6	84
110	A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 900-906.	2.7	83
111	Apolipoprotein E $\epsilon$ 4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias. <i>Archives of Neurology</i> , 1999, 56, 961.	4.5	82
112	Profile of Neuropsychological Deficits in Older Stroke Survivors without Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 52-56.	1.5	82
113	Language impairment in dementia: impact on symptoms and care needs in residential homes. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 1002-1006.	2.7	81
114	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	1.9	78
115	Early and Presenting Symptoms of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 202-208.	1.5	77
116	Association Between Mild Vascular Cognitive Impairment and Impaired Activities of Daily Living in Older Stroke Survivors Without Dementia. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 103-107.	2.6	75
117	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 512-519.	1.9	75
118	A role for APP in Wnt signalling links synapse loss with $\beta$ -amyloid production. <i>Translational Psychiatry</i> , 2018, 8, 179.	4.8	74
119	Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 726-733.	1.2	73
120	The Effect of Staff Training on Agitation and Use of Restraint in Nursing Home Residents With Dementia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 80-86.	2.2	72
121	Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 628-636.	2.7	71
122	Epidemiology of Pain in People With Dementia Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 453.e1-453.e6.	2.5	70
123	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019, 50, 72-80.	10.9	70
124	Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 442-445.	3.8	69
125	Update on Vascular Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 281-301.	2.3	69
126	Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. <i>Behavioural Brain Research</i> , 2005, 161, 299-305.	2.2	68



#	ARTICLE	IF	CITATIONS
127	Diagnosing dementia with Lewy bodies. <i>Lancet, The</i> , 1999, 354, 1227-1228.	13.7	67
128	Impact of Behavioral and Psychological Symptoms of Dementia on Caregivers. <i>International Psychogeriatrics</i> , 2000, 12, 93-105.	1.0	67
129	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 46-54.	2.7	67
130	Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 711-719.	1.3	67
131	Current prevalence of dementia, depression and behavioural problems in the older adult care home sector: the South East London Care Home Survey. <i>Age and Ageing</i> , 2014, 43, 562-567.	1.6	66
132	Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. <i>Movement Disorders</i> , 2016, 31, 352-359.	3.9	66
133	The Prevalence of Autonomic Symptoms in Dementia and Their Association with Physical Activity, Activities of Daily Living and Quality of Life. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 230-237.	1.5	65
134	The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1030-1038.	2.7	65
135	Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1361-1369.	2.7	65
136	Stroke and cognition. <i>Current Atherosclerosis Reports</i> , 2001, 3, 334-339.	4.8	64
137	Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. <i>Age and Ageing</i> , 2008, 37, 547-552.	1.6	64
138	Short- and Long-term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 321-331.	1.2	64
139	Associations between cognitively stimulating leisure activities, cognitive function and age-related cognitive decline. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 422-430.	2.7	64
140	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1139-1152.	2.6	63
141	A Detailed Phenomenological Comparison of Complex Visual Hallucinations in Dementia With Lewy Bodies and Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1997, 9, 381-388.	1.0	62
142	Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. <i>Neurology</i> , 2007, 69, S23-8.	1.1	62
143	Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. <i>BMJ, The</i> , 2014, 349, g6420-g6420.	6.0	62
144	Psychosis in Alzheimer disease – mechanisms, genetics and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2022, 18, 131-144.	10.1	62

#	ARTICLE	IF	CITATIONS
145	Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. <i>International Psychogeriatrics</i> , 2009, 21, 216.	1.0	61
146	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021, 385, 309-319.	27.0	61
147	Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot "Prevention of Decline in Cognition after Stroke Trial"™ (PODCAST) Randomised Controlled Trial. <i>PLoS ONE</i> , 2017, 12, e0164608.	2.5	60
148	Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2006, 21, 50-56.	4.4	59
149	Psychotic symptoms in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 743-752.	2.7	58
150	Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. <i>Consciousness and Cognition</i> , 2002, 11, 461-474.	1.5	58
151	Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006, 27, 433-438.	3.1	58
152	Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 167-175.	1.5	57
153	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016, 6, e010357.	1.9	57
154	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020, 32, 705-717.	1.0	57
155	Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 140-145.	2.7	55
156	Neuropsychiatric Correlates of Cerebrospinal Fluid Biomarkers in Alzheimer's™ Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 559-563.	1.5	54
157	Treatment of Behavioral and Psychological Symptoms of Alzheimer's™ Disease. <i>Current Treatment Options in Neurology</i> , 2012, 14, 113-125.	1.8	54
158	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. <i>Drugs and Aging</i> , 2013, 30, 603-611.	2.7	54
159	The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. <i>British Journal of Psychiatry</i> , 2020, 216, 43-48.	2.8	54
160	High Prevalence of Orthostatic Hypotension in Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 307-313.	1.5	53
161	Involvement of $\alpha 6/\beta 3$ neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [ <sup>125</sup> I]- $\alpha$ -conotoxin MII binding in the thalamus and striatum.. <i>Neuroscience Letters</i> , 2004, 372, 220-225.	2.1	51
162	CSF amyloid $\beta$ 38 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 160-164.	1.9	50

#	ARTICLE	IF	CITATIONS
163	New and emerging treatments for Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 535-543.	2.8	50
164	Long-Term Mortality in a Cohort of Home-Dwelling Elderly with Mild Alzheimer's Disease and Lewy Body Dementia. Dementia and Geriatric Cognitive Disorders, 2014, 38, 161-169.	1.5	50
165	Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2014, 15, 1797-1810.	1.8	50
166	Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial. International Journal of Geriatric Psychiatry, 2017, 32, 1094-1103.	2.7	50
167	The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). Journal of the American Medical Directors Association, 2019, 20, 330-339.	2.5	50
168	The characterisation and impact of "fluctuating" cognition in dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2001, 16, 494-498.	2.7	49
169	End-of-life care and dementia. Reviews in Clinical Gerontology, 2005, 15, 135-148.	0.5	49
170	Synergistic effect of apolipoprotein E $\epsilon$ 4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and Genomics, 2008, 18, 289-298.	1.5	49
171	Synaptic proteins in CSF relate to Parkinson's disease stage markers. Npj Parkinson's Disease, 2017, 3, 7.	5.3	49
172	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 232-241.	1.7	49
173	Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. Biological Psychiatry, 2001, 49, 130-136.	1.3	48
174	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson's Disease Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 26, 330-338.	1.5	48
175	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the Tj ETQq1 1 0.784314 rgBT /Overloc	2.7	48
176	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS ONE, 2017, 12, e0179521.	2.5	48
177	Mental health of people living with dementia in care homes during COVID-19 pandemic. International Psychogeriatrics, 2020, 32, 1253-1254.	1.0	48
178	Depressive Symptoms in Alzheimer's Disease and Lewy Body Dementia: A One-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders, 2011, 32, 143-149.	1.5	47
179	Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open, 2014, 4, e005158-e005158.	1.9	47
180	A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. International Psychogeriatrics, 2015, 27, 1849-1859.	1.0	47

#	ARTICLE	IF	CITATIONS
181	COSMOSâ€™ improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. <i>Implementation Science</i> , 2015, 10, 131.	6.9	46
182	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 898.e1-898.e7.	2.5	46
183	Utility, reliability, sensitivity and validity of an online test system designed to monitor changes in cognitive function in clinical trials. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, e83-e92.	2.7	46
184	ANXIETY DISORDERS IN DEMENTIA SUFFERERS. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 987-990.	2.7	45
185	Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 101-106.	2.8	45
186	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease â€” a multicentre RCT. <i>Trials</i> , 2009, 10, 57.	1.6	44
187	Pharmacological profile of an essential oil derived from <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 377-384.	2.4	44
188	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 143-152.	2.4	44
189	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020, 11, 579934.	2.6	44
190	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013, 202, 121-128.	2.8	43
191	A Prospective Study of Psychotic Symptoms in Dementia Sufferers: Psychosis in Dementia. <i>International Psychogeriatrics</i> , 1997, 9, 57-64.	1.0	42
192	Depression in the carers of dementia sufferers: a comparison of the carers of patients suffering from dementia with Lewy Bodies and the carers of patients with Alzheimerâ€™s disease. <i>Journal of Affective Disorders</i> , 2000, 59, 61-65.	4.1	42
193	Aromatherapy in dementia. <i>Advances in Psychiatric Treatment</i> , 2004, 10, 296-300.	0.5	42
194	Drug repurposing for Alzheimerâ€™s disease based on transcriptional profiling of human iPSC-derived cortical neurons. <i>Translational Psychiatry</i> , 2019, 9, 220.	4.8	42
195	Hyperintensities and Fronto-Subcortical Atrophy on MRI Are Substrates of Mild Cognitive Deficits after Stroke. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 113-118.	1.5	41
196	Treatment of Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Drugs and Aging</i> , 2011, 28, 769-777.	2.7	41
197	Cortical Changes Associated with Depression and Antidepressant Use in Alzheimer and Lewy Body Dementia: An MRI Surface-based Morphometric Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 4-13.e1.	1.2	41
198	Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. <i>Neurobiology of Aging</i> , 2014, 35, 1513.e1-1513.e5.	3.1	41

#	ARTICLE	IF	CITATIONS
199	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 352-365.	3.2	41
200	FITS into practice: translating research into practice in reducing the use of anti-psychotic medication for people with dementia living in care homes. <i>Aging and Mental Health</i> , 2016, 20, 709-718.	2.8	41
201	Early Discriminatory Diagnosis of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 195-205.	1.5	40
202	A failure of "Pop-Out"™ in visual search tasks in dementia with Lewy Bodies as compared to Alzheimer's and Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 763-772.	2.7	39
203	BuChE and APOE $\epsilon$ 4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. <i>Movement Disorders</i> , 2009, 24, 392-400.	3.9	39
204	Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of $\alpha$ -synuclein neuropathology required and feasible?. <i>Brain Research Reviews</i> , 2010, 65, 28-55.	9.0	39
205	Associations of Awareness of Age-Related Change With Emotional and Physical Well-being: A Systematic Review and Meta-analysis. <i>Gerontologist</i> , The, 2020, 60, e477-e490.	3.9	39
206	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	2.6	39
207	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2008, 60, 1515-1522.	2.4	39
208	Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 141-148.	1.2	38
209	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 75-86.	1.2	38
210	A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. <i>Journal of Affective Disorders</i> , 2002, 69, 219-223.	4.1	37
211	Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cough?. <i>International Psychogeriatrics</i> , 2005, 17, 4-12.	1.0	37
212	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	2.8	37
213	Choline Acetyltransferase Activity in Vascular Dementia and Stroke. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 233-238.	1.5	36
214	Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1054-1061.	2.7	36
215	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	3.9	36
216	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 273.	4.8	36

#	ARTICLE	IF	CITATIONS
217	The prevalence of depression in the carers of dementia sufferers. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 237-242.	2.7	35
218	Aggressive Behavior and Neuroleptic Medication Are Associated With Increased Number of Alpha1-Adrenoceptors in Patients With Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 435-437.	1.2	35
219	Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. <i>Neurobiology of Aging</i> , 2013, 34, 2441.e1-2441.e5.	3.1	35
220	Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer's Disease. <i>Pharmaceuticals</i> , 2013, 6, 1304-1321.	3.8	35
221	Protocol for the IDEAL-2 longitudinal study: following the experiences of people with dementia and their primary carers to understand what contributes to living well with dementia and enhances active life. <i>BMC Public Health</i> , 2018, 18, 1214.	2.9	35
222	Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 935-946.	2.9	35
223	Subtle Attentional Deficits in the Absence of Dementia Are Associated with an Increased Risk of Post-Operative Delirium. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 390-394.	1.5	34
224	Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 683-695.	2.8	34
225	Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. <i>Journal of Neurology</i> , 2009, 256, 717-720.	3.6	33
226	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. <i>CNS Drugs</i> , 2016, 30, 1097-1109.	5.9	33
227	Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. <i>Brain</i> , 2009, 132, 1858-1865.	7.6	32
228	Multidisciplinary research priorities for the COVID-19 pandemic – Authors' reply. <i>Lancet Psychiatry</i> , 2020, 7, e44-e45.	7.4	32
229	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 47.	6.2	32
230	Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. <i>Neuroscience Letters</i> , 2002, 317, 13-16.	2.1	31
231	Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. <i>Journal of Neural Transmission</i> , 2008, 115, 869-878.	2.8	31
232	Amyloid $\beta^2$ concentrations in older people with Down syndrome and dementia. <i>Neuroscience Letters</i> , 2009, 451, 162-164.	2.1	31
233	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 398, 1487-1497.	13.7	31
234	Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 278-286.	1.5	30

#	ARTICLE	IF	CITATIONS
235	Helping staff to implement psychosocial interventions in care homes: augmenting existing practices and meeting needs for support. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 284-293.	2.7	30
236	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 164-174.	3.7	30
237	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021, 26, 5797-5811.	7.9	30
238	Dementia with Lewy Bodies. <i>Drugs and Aging</i> , 2001, 18, 397-407.	2.7	29
239	Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. <i>Neuroscience Letters</i> , 2013, 557, 177-180.	2.1	29
240	Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 22-31.	2.7	29
241	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2015, 27, 181-197.	1.0	29
242	Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 231.	2.1	28
243	Quantifying the association between computerised measures of attention and confusion assessment method defined delirium: a prospective study of older orthopaedic surgical patients, free of dementia. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 1253-1260.	2.7	28
244	Increased neural progenitors in vascular dementia. <i>Neurobiology of Aging</i> , 2011, 32, 2152-2161.	3.1	28
245	New Therapeutic Strategies for Lewy Body Dementias. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 68.	4.2	28
246	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 116.	6.2	28
247	Psychosis in Alzheimer's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 57.	4.2	28
248	Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. <i>Age and Ageing</i> , 2021, 50, 457-464.	1.6	28
249	Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 300.	1.6	27
250	Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. <i>Brain Pathology</i> , 2020, 30, 191-202.	4.1	27
251	Intraoperative Optimization of Both Depth of Anesthesia and Cerebral Oxygenation in Elderly Patients Undergoing Coronary Artery Bypass Graft Surgery: A Randomized Controlled Pilot Trial. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1172-1181.	1.3	27
252	( <sup>123</sup> I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. <i>BMJ Open</i> , 2013, 3, e002642.	1.9	26

#	ARTICLE	IF	CITATIONS
253	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with $\beta^2$ -amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016, 9, 84.	2.6	26
254	Investigating the relationship between age of onset of depressive disorder and cognitive function. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 38-46.	2.7	26
255	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021, 36, 89-101.	5.7	26
256	Antipsychotics and Mortality in Dementia. <i>American Journal of Psychiatry</i> , 2012, 169, 7-9.	7.2	25
257	New and emerging treatments for Alzheimer's disease. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 147-156.	2.4	25
258	Increased Transforming Growth Factor $\beta^2$ in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble $A\beta^{242}$ Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	2.6	25
259	Agitation and impulsivity in mid and late life as possible risk markers for incident dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12016.	3.7	25
260	End of life treatment decisions in people with dementia: carers' views and the factors which influence them. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 1005-1008.	2.7	24
261	Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 284.	1.6	24
262	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 101-110.	2.6	24
263	PIMAVANSERIN IN ALZHEIMER'S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMS. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2019, 6, 1-7.	2.7	24
264	Analgesic treatments in people with dementia - how safe are they? A systematic review. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 511-522.	2.4	24
265	International relevance of two measures of awareness of age-related change (AARC). <i>BMC Geriatrics</i> , 2020, 20, 359.	2.7	24
266	A prospective study of dementia with Lewy bodies. <i>Age and Ageing</i> , 1998, 27, 631-636.	1.6	23
267	The Relationship between Post-Natal Depression, Somatization and Behaviour in Malaysian Women. <i>Transcultural Psychiatry</i> , 2001, 38, 27-34.	1.6	23
268	Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 100-106.	2.2	23
269	Preventing dementia. <i>Advances in Psychiatric Treatment</i> , 2005, 11, 176-183.	0.5	22
270	The K Variant of the Butyrylcholinesterase Gene Is Associated with Reduced Phosphorylation of Tau in Dementia Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 357-360.	1.5	22



#	ARTICLE	IF	CITATIONS
271	Familial Occurrence of Dementia and Parkinsonism. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 288-295.	1.5	22
272	Core and Suggestive Symptoms of Dementia with Lewy Bodies Cluster in Persons with Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 317-324.	1.5	22
273	Prescription of antipsychotics in people with dementia. <i>British Journal of Psychiatry</i> , 2014, 205, 4-5.	2.8	22
274	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 40-48.	2.3	22
275	Reduced thermal sensitivity and increased opioidergic tone in the TASTPM mouse model of Alzheimer's disease. <i>Pain</i> , 2016, 157, 2285-2296.	4.2	22
276	The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 461-467.	2.8	22
277	Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). <i>Drugs and Aging</i> , 2018, 35, 545-558.	2.7	22
278	The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 604-609.	2.5	22
279	An online investigation of the relationship between the frequency of word puzzle use and cognitive function in a large sample of older adults. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 921-931.	2.7	22
280	Neuropsychological Deficits in Older Stroke Patients. <i>Annals of the New York Academy of Sciences</i> , 2002, 977, 179-182.	3.8	21
281	Apathy and Its Response to Antipsychotic Review and Nonpharmacological Interventions in People With Dementia Living in Nursing Homes: WHELD, a Factorial Cluster Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 741-747.	2.5	21
282	Improving the quality of life of care home residents with dementia: Cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 282-291.	0.8	21
283	Expression of neurogenic markers in Alzheimer's disease: a systematic review and metatranscriptional analysis. <i>Neurobiology of Aging</i> , 2019, 76, 166-180.	3.1	21
284	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2257-2263.	2.6	21
285	Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. <i>Brain Pathology</i> , 2021, 31, 253-266.	4.1	21
286	Cross-sectional association between objective cognitive performance and perceived age-related gains and losses in cognition. <i>International Psychogeriatrics</i> , 2021, 33, 727-741.	1.0	21
287	Cognitive decline in a prospectively studied group of stroke survivors, with a particular emphasis on the >75's. <i>Age and Ageing</i> , 2002, 31, 24-27.	1.6	20
288	Î±-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010, 22, 321-327.	1.0	20

#	ARTICLE	IF	CITATIONS
289	What influences the sustainability of an effective psychosocial intervention for people with dementia living in care homes? A 9 to 12-month follow-up of the perceptions of staff in care homes involved in the WHELD randomised controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 674-682.	2.7	20
290	Dementia Care Mapping, to reduce agitation in care home residents with dementia: the EPIC cluster RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-172.	2.8	20
291	Correlation of Entorhinal Amyloid with Memory in Alzheimer's and Vascular but Not Lewy Body Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 57-60.	1.5	19
292	Agitation and Psychosis in Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 913-917.	1.2	19
293	Cerebrospinal Fluid Levels of sAPP $\beta$ and sAPP $\beta$ 2 in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-6.	2.0	19
294	Genetic Associations of Autopsy-Confirmed Vascular Dementia Subtypes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 247-253.	1.5	19
295	A Pilot Study Examining Associations between DYRK1A and $\beta$ -Synuclein Dementias. <i>Neurodegenerative Diseases</i> , 2012, 10, 229-231.	1.4	19
296	Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 580-586.	1.2	19
297	A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD). <i>Journal of the American Medical Association</i> , 2015, 316, 316-322.	2.5	19
298	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 793-801.	2.6	19
299	Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 728-730.	1.9	19
300	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 345-355.	2.6	19
301	Neurogenic marker abnormalities in the hippocampus in dementia with Lewy bodies. <i>Hippocampus</i> , 2011, 21, 1126-1136.	1.9	18
302	Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 327-329.	2.8	18
303	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	1.9	18
304	Anxiety disorder in dementia. <i>Irish Journal of Psychological Medicine</i> , 1994, 11, 108-109.	1.0	17
305	Feasibility of a staff training and support programme to improve pain assessment and management in people with dementia living in care homes. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 221-231.	2.7	17
306	Placement of dementia sufferers in residential and nursing home care. <i>Age and Ageing</i> , 1998, 27, 189-193.	1.6	16

#	ARTICLE	IF	CITATIONS
307	Neuropsychiatric aspects of alzheimer's disease. <i>Current Psychiatry Reports</i> , 1999, 1, 49-60.	4.5	16
308	The Extended & Tau Haplotype and the Age of Onset of Dementia in Down Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 199-202.	1.5	16
309	Subtle deficits of attention after surgery: quantifying indicators of sub syndrome delirium. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 945-952.	2.7	16
310	Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , 2013, 14, 401.	1.6	16
311	LIVE@Home.Path innovating the clinical pathway for home-dwelling people with dementia and their caregivers: study protocol for a mixed-method, stepped-wedge, randomized controlled trial. <i>Trials</i> , 2020, 21, 510.	1.6	16
312	Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. <i>Synapse</i> , 2007, 61, 903-911.	1.2	15
313	NOS3 gene rs1799983 polymorphism and incident dementia in elderly stroke survivors. <i>Neurobiology of Aging</i> , 2011, 32, 554.e1-554.e6.	3.1	15
314	Feasibility study of an optimised person-centred intervention to improve mental health and reduce antipsychotics amongst people with dementia in care homes: study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 13.	1.6	15
315	Exploratory analysis of seven Alzheimer's disease genes: disease progression. <i>Neurobiology of Aging</i> , 2013, 34, 1310.e1-1310.e7.	3.1	15
316	Cost-Effectiveness of Dementia Care Mapping in Care-Home Settings: Evaluation of a Randomised Controlled Trial. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 237-247.	2.1	15
317	Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. <i>BMC Medicine</i> , 2020, 18, 351.	5.5	15
318	Online Education and Cognitive Behavior Therapy Improve Dementia Caregivers' Mental Health: A Randomized Trial. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1403-1409.e1.	2.5	15
319	Associations of subjective cognitive and memory decline with depression, anxiety, and two-year change in objectively-assessed global cognition and memory. <i>Aging, Neuropsychology, and Cognition</i> , 2022, 29, 840-866.	1.3	15
320	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014, 3, 108.	1.6	15
321	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018, 15, 883-891.	1.4	15
322	Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-98.	1.0	15
323	VARIABLES WHICH DISTINGUISH PATIENTS FULFILLING CLINICAL CRITERIA FOR DEMENTIA WITH LEWY BODIES FROM THOSE WITH ALZHEIMER'S DISEASE. , 1997, 12, 314-318.		14
324	Definition and Diagnosis of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 15-24.	1.5	14

#	ARTICLE	IF	CITATIONS
325	Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 464.e1-464.e7.	2.5	14
326	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 373-386.	2.6	14
327	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 283-293.	1.5	14
328	Ras-ERK-ETS inhibition alleviates neuronal mitochondrial dysfunction by reprogramming mitochondrial retrograde signaling. <i>PLoS Genetics</i> , 2018, 14, e1007567.	3.5	14
329	Homocysteine and post-stroke cognitive decline. <i>Age and Ageing</i> , 2007, 36, 339-343.	1.6	13
330	The cost of care homes for people with dementia in England: a modelling approach. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1466-1475.	2.7	13
331	Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex. <i>Neurobiology of Aging</i> , 2020, 89, 83-88.	3.1	13
332	Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. <i>Alzheimer's and Dementia</i> , 2020, 16, e042909.	0.8	13
333	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12098.	2.4	13
334	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 573-584.	1.2	13
335	Cognitive Decline in Down Syndrome—Reply. <i>Archives of Neurology</i> , 2003, 60, 1024.	4.5	12
336	The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs. <i>Evidence-Based Medicine</i> , 2014, 19, 140-140.	0.6	12
337	Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1-9.	2.7	12
338	Psychiatric sequelae of MDMA (ecstasy) and related drugs. <i>Irish Journal of Psychological Medicine</i> , 1994, 11, 132-133.	1.0	11
339	Mild Cognitive Impairment and Vascular Cognitive Impairment in Stroke Patients. <i>International Psychogeriatrics</i> , 2003, 15, 123-126.	1.0	11
340	Person-centred care and care mapping in dementia. <i>Lancet Neurology</i> , The, 2009, 8, 302-303.	10.2	11
341	Analysis of Neuron-Specific Enolase and S100B as Biomarkers of Cognitive Decline Following Surgery in Older People. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 307-311.	1.5	11
342	Emerging amyloid and tau targeting treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 697-711.	2.8	11

#	ARTICLE	IF	CITATIONS
343	PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trial. <i>Trials</i> , 2017, 18, 583.	1.6	11
344	Alcohol and dementia: a complex relationship with potential for dementia prevention. <i>Lancet Public Health</i> , The, 2018, 3, e103-e104.	10.0	11
345	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1146-1152.	2.7	11
346	The cross-sectional relationship between pain and awareness of age-related changes. <i>British Journal of Pain</i> , 2020, 15, 204946372096179.	1.5	11
347	The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1726-1737.	3.9	11
348	Relationship between self-perceptions of aging and "living well" among people with mild-to-moderate dementia: Findings from the ideal programme. <i>Archives of Gerontology and Geriatrics</i> , 2021, 94, 104328.	3.0	11
349	Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. <i>Neuroscience Letters</i> , 2008, 442, 297-299.	2.1	10
350	CSF $\alpha$ -synuclein as a diagnostic biomarker for Parkinson disease and related dementias. <i>Neurology</i> , 2010, 75, 1760-1761.	1.1	10
351	Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. <i>Journal of Neural Transmission</i> , 2012, 119, 1467-1476.	2.8	10
352	Cognitive Impairment in Studies of 5HTTLPR and Psychosis in Alzheimer's Disease: A Systematic Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 155-164.	1.5	10
353	The relationship between the frequency of number puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 932-940.	2.7	10
354	Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1402-1408.	2.7	10
355	Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 25-31.	2.2	10
356	Minocycline 200mg or 400mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-62.	0.7	10
357	Traumatic life experiences and post-traumatic stress symptoms in middle-aged and older adults with and without autistic traits. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	10
358	Differences in awareness of positive and negative age-related changes accounting for variability in health outcomes. <i>European Journal of Ageing</i> , 2022, 19, 1087-1097.	2.8	10
359	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.	0.8	9
360	Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. <i>Drug Safety</i> , 2019, 42, 1471-1485.	3.2	9

#	ARTICLE	IF	CITATIONS
361	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. <i>Frontiers in Neurology</i> , 2020, 11, 541377.	2.4	9
362	Relevance of sleep and associated structural changes in GBA1 mouse to human rapid eye movement behavior disorder. <i>Scientific Reports</i> , 2022, 12, 7973.	3.3	9
363	Is apolipoprotein e4 associated with cognitive decline in depression?. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 436-437.	2.7	8
364	An Intron 7 Polymorphism in <i>APP</i> Affects the Age of Onset of Dementia in Down Syndrome. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-5.	2.0	8
365	Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 941-943.	4.1	8
366	Cognitive and neuroimaging predictors of AD and stroke. <i>Nature Reviews Neurology</i> , 2013, 9, 605-606.	10.1	8
367	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 303-313.	2.6	8
368	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 916.	2.4	8
369	Effectiveness of Dementia Care Mapping to reduce agitation in care home residents with dementia: an open-cohort cluster randomised controlled trial. <i>Aging and Mental Health</i> , 2021, 25, 1410-1423.	2.8	8
370	Lower cognitive baseline scores predict cognitive training success after 6 months in healthy older adults: Results of an online RCT. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1000-1008.	2.7	8
371	The impact of auditory hallucinations on living well with dementia: Findings from the IDEAL programme. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1370-1377.	2.7	8
372	Exploring awareness of age-related changes among over 50s in the UK: findings from the PROTECT study. <i>International Psychogeriatrics</i> , 2021, , 1-15.	1.0	8
373	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2022, 152, 105251.	3.8	8
374	Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid A $\beta$ <sub>40</sub> and tau in patients with intractable unipolar depression. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1283-1291.	2.7	7
375	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012, 531, 1-4.	2.1	7
376	Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 779-786.	3.1	7
377	Alzheimer's Disease Progression in the 5 $\times$ FAD Mouse Captured with a Multiplex Gene Expression Array. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1177-1191.	2.6	7
378	Executive function but not episodic memory decline associated with visual hallucinations in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2020, 14, 85-97.	1.4	7

#	ARTICLE	IF	CITATIONS
379	Whole transcriptome in silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side effects. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12078.	3.7	7
380	Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies. <i>Health Technology Assessment</i> , 2021, 25, 1-202.	2.8	7
381	In vivo multi-parametric manganese-enhanced MRI for detecting amyloid plaques in rodent models of Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 12419.	3.3	7
382	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. <i>Autism Research</i> , 2020, 13, 641-654.	3.8	7
383	Trajectories of cognitive change following stroke: stepwise decline towards dementia in the elderly. <i>Brain Communications</i> , 2022, 4, .	3.3	7
384	Anti-psychotic drug use in older people. <i>Age and Ageing</i> , 2002, 31, 225-226.	1.6	6
385	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-412.	0.8	6
386	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. <i>Trials</i> , 2016, 17, 324.	1.6	6
387	Predictors of changes after reasoning training in healthy adults. <i>Brain and Behavior</i> , 2020, 10, e01861.	2.2	6
388	Role of the Extended MAPT Haplotype in the Worsening of Psychotic Symptoms and Treatment Response in Alzheimer Disease. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 934-937.	2.5	5
389	Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). <i>Trials</i> , 2015, 16, 509.	1.6	5
390	Psychiatric and neuropsychiatric syndromes and COVID-19. <i>Lancet Psychiatry</i> , 2020, 7, 663-664.	7.4	5
391	Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis. <i>Journal of Affective Disorders</i> , 2022, 309, 437-445.	4.1	5
392	Factors influencing general practitioner referral to a child psychiatric service. <i>Irish Journal of Psychological Medicine</i> , 1993, 10, 144-147.	1.0	4
393	Melissa aromatherapy as safe and effective treatment. <i>Nursing and Residential Care</i> , 2003, 5, 80-82.	0.1	4
394	Antipsychotics in patients with Alzheimer's disease—what is their clinical value?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 248-249.	2.5	4
395	Dementia: challenges and promising developments. <i>Lancet Neurology</i> , 2011, 10, 7-9.	10.2	4
396	Transcription-based drug repurposing for COVID-19. <i>Virus Research</i> , 2020, 290, 198176.	2.2	4

#	ARTICLE	IF	CITATIONS
397	Reducing psychotropic drug use in people with dementia living in nursing homes. <i>International Psychogeriatrics</i> , 2020, 32, 291-294.	1.0	4
398	What does feeling younger or older than one's chronological age mean to men and women? Qualitative and quantitative findings from the PROTECT study. <i>Psychology and Health</i> , 2023, 38, 324-347.	2.2	4
399	Predictors of activities of daily living in healthy older adults: Who benefits most from online cognitive training?. <i>Brain and Behavior</i> , 2021, 11, e2388.	2.2	4
400	Risky drinking and cognitive impairment in community residents aged 50 and over. <i>Aging and Mental Health</i> , 2022, 26, 2432-2439.	2.8	4
401	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts. <i>British Journal of Psychiatry</i> , 2022, 221, 722-731.	2.8	4
402	The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 11, 23-8.	2.2	4
403	A Randomized Controlled Trial of a Digital Adaptation of the WHELD Person-Centered Nursing Home Training Program. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1166-1170.	2.5	4
404	Cost-Effectiveness of an Online Intervention for Caregivers of People Living With Dementia. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1468-1473.	2.5	4
405	New guidelines on disorders associated with dementia. <i>Nature Reviews Neurology</i> , 2012, 8, 663-664.	10.1	3
406	Dynamin protein in stroke and vascular dementia. <i>Neuroscience Letters</i> , 2014, 563, 118-122.	2.1	3
407	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	2.8	3
408	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review – CORRIGENDUM. <i>International Psychogeriatrics</i> , 2014, 26, 1099-1099.	1.0	3
409	Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1233.	7.4	3
410	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016, 6, 733-739.	2.8	3
411	Historical landmarks in dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2017, 16, 348.	10.2	3
412	Healthy adjustment for new residents with dementia using SettleIN: A feasibility study in UK care homes. <i>Dementia</i> , 2020, 19, 1811-1828.	2.0	3
413	Cross-Sectional and Longitudinal Associations between Subjective Sleep Difficulties and Self-Perceptions of Aging. <i>Behavioral Sleep Medicine</i> , 2022, 20, 732-761.	2.1	3
414	Healthcare utilisation and physical activities for older adults with comorbidities in the UK during COVID-19. <i>Health and Social Care in the Community</i> , 2021, , .	1.6	3



#	ARTICLE	IF	CITATIONS
415	Impact of Psychotic Symptoms and Concurrent Neuropsychiatric Symptoms on the Quality of Life of People With Dementia Living in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1474-1479.e1.	2.5	3
416	Self-harm and Suicidality Experiences of Middle-Age and Older Adults With vs. Without High Autistic Traits. <i>Journal of Autism and Developmental Disorders</i> , 2023, 53, 3034-3046.	2.7	3
417	The Charles Bonnet Syndrome associated with vascular pathology â€“ a classical presentation with a very atypical course. <i>Irish Journal of Psychological Medicine</i> , 1991, 8, 44-45.	1.0	2
418	The phenomena of â€œbingeingâ€•. <i>Irish Journal of Psychological Medicine</i> , 1992, 9, 61-62.	1.0	2
419	Prevalence of abnormal eating amongst elderly people in residential care. , 2000, 15, 283-284.		2
420	Cholinesterase inhibitors in the treatment of dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 458-459.	2.7	2
421	Alzheimer's disease â€“ a vascular dementia?. <i>Reviews in Clinical Gerontology</i> , 2003, 13, .	0.5	2
422	Effectiveness of collaborative care for elderly adults with Alzheimer's disease in primary care. <i>Lancet Neurology</i> , The, 2006, 5, 644-645.	10.2	2
423	Clinical management of dementia. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 88-93.	0.2	2
424	Information provision services in dementia care. <i>International Journal of Older People Nursing</i> , 2011, 6, 217-226.	1.3	2
425	Screening for dementia: an opportunity for debate. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1347-1349.	2.8	2
426	Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. <i>International Psychogeriatrics</i> , 2013, 25, 687-689.	1.0	2
427	P3â€“554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATIONâ€“BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1335.	0.8	2
428	P4â€“017: CLINICAL TRIAL PIPELINES FOR ALZHEIMER'S DISEASE POSE CHALLENGES FOR FUTURE EFFECTIVE TREATMENT AND THERAPIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1439.	0.8	2
429	O4â€“03â€“06: A RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF AN Eâ€“LEARNING INTERVENTION BASED ON THE IMPROVING WELLâ€“BEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSONâ€“CENTRED CARE TRAINING PROGRAMME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1406.	0.8	2
430	P3â€“023: BEYOND ANTIPSYCHOTICS: EXPLORING EFFICACY AND HARMS OF Zâ€“DRUGS FOR SLEEP DISTURBANCE ON THE PROGRESSION OF KEY DEMENTIA OUTCOMES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1072.	0.8	2
431	Computerized neuropsychological tests undertaken on digital platforms are cost effective, achieve high engagement, distinguish and are highly sensitive to longitudinal change: Data from the PROTECT and GBIT studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041122.	0.8	2
432	Genetic risk, education and incidence of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e045903.	0.8	2

#	ARTICLE	IF	CITATIONS
433	Reply: Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2021, 144, e73.	7.6	2
434	Diagnosing Dementia-Related Psychosis. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	2.2	2
435	Christmas census at a district general hospital psychiatric unit. <i>Irish Journal of Psychological Medicine</i> , 1991, 8, 46-47.	1.0	1
436	Non-Alzheimer dementias. <i>Current Opinion in Psychiatry</i> , 2000, 13, 409-414.	6.3	1
437	Neurochemistry of severe dementia. <i>Reviews in Clinical Gerontology</i> , 2005, 15, 105-123.	0.5	1
438	Current perspectives in dementia with Lewy bodies. <i>Aging Health</i> , 2006, 2, 461-472.	0.3	1
439	Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer's disease. <i>Evidence-Based Mental Health</i> , 2009, 12, 20-20.	4.5	1
440	Video decision support affects patients' care choices in dementia care planning. <i>Evidence-Based Mental Health</i> , 2010, 13, 12-12.	4.5	1
441	Biomarkers for dementia diagnosis: differentiating DLB and FTD may be difficult. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1037-1037.	1.9	1
442	Improving diagnosis of possible DLB. <i>Neurology</i> , 2013, 81, 1730-1731.	1.1	1
443	A small proportion of people with dementia and neuropsychiatric symptoms experience clinically significant worsening when antidepressants are discontinued. <i>Evidence-Based Medicine</i> , 2013, 18, 27-28.	0.6	1
444	Evidence-based prevention and treatment of dementia – Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 1007-1008.	10.2	1
445	[P1's299]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P367.	0.8	1
446	[P1's564]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P510.	0.8	1
447	P1's658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P595.	0.8	1
448	P4's622: DEMENTIA HOSPITAL CARE RESEARCH PROGRAMME: PERI-OPERATIVE ENHANCED RECOVERY HIP FRACTURE CARE OF PATIENTS WITH DEMENTIA (PERFECTED) – CLUSTER RANDOMISED CONTROL TRIAL RESULTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P1565.	0.8	1
449	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020, 11, 602480.	2.6	1
450	Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. <i>Alzheimer's and Dementia</i> , 2020, 16, e039139.	0.8	1

#	ARTICLE	IF	CITATIONS
451	Higher perceived age-related gains and losses relate to lower objective cognitive scores. <i>Alzheimer's and Dementia</i> , 2020, 16, e043999.	0.8	1
452	Impact of psychosis on quality of life and well-being in dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e045871.	0.8	1
453	Investigating the effects of impairment in non-verbal communication on neuropsychiatric symptoms and quality of life of people living with dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12172.	3.7	1
454	PERFECTED enhanced recovery pathway (PERFECT-ER) versus standard acute hospital care for people after hip fracture surgery who have cognitive impairment: a feasibility cluster randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e055267.	1.9	1
455	The impact of the COVID-19 pandemic on cognitive health. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
456	Letter to the editor. <i>Acta Psychiatrica Scandinavica</i> , 1990, 81, 96-96.	4.5	0
457	Sexual abuse: Crisis and response to counselling. <i>Journal of Forensic Psychiatry Psychology</i> , 1991, 2, 211-216.	0.3	0
458	ABC of Monitoring Drug Therapy. By J. K. Aronson, M. Hardman and D. J. M. Reynolds London: BMJ. 1993. 38 pp. £6.95.. <i>British Journal of Psychiatry</i> , 1994, 165, 283-283.	2.8	0
459	Antidepressants in the elderly: a review. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 51-63.	4.1	0
460	Clinical management of dementia. <i>Psychiatry (Abingdon, England)</i> , 2004, 3, 27-32.	0.2	0
461	Dementia with Lewy Bodies and Parkinson's Disease Dementia Editors: JOHN O'BRIEN, IAN MCKEITH, DAVID AMES AND EDMOND CHIU, London, Taylor and Francis, 2005, £75.00 Hard cover, pp. 264 ISBN 1 8418 4491 8. <i>International Psychogeriatrics</i> , 2006, 18, 763-764.	1.0	0
462	Time to discontinuation similar for atypical antipsychotic drugs and placebo in people with Alzheimer's disease. <i>Evidence-Based Mental Health</i> , 2007, 10, 58-58.	4.5	0
463	Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S7794.	0.4	0
464	Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies – ADDENDUM. <i>International Psychogeriatrics</i> , 2014, 26, 1753-1753.	1.0	0
465	Better together for better dementia research and care. <i>Lancet Psychiatry</i> , 2016, 3, 503-504.	7.4	0
466	Non-Alzheimer Dementias. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 247-248.	2.3	0
467	Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches. <i>Evidence-Based Medicine</i> , 2016, 21, 25-25.	0.6	0
468	[P1-309]: PREVALENCE AND COMORBIDITY OF APATHY AND DEPRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P371.	0.8	0

#	ARTICLE	IF	CITATIONS
469	[P1â€“235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBâ€“UNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P333.	0.8	0
470	[P2â€“581]: THE RELATIONSHIP BETWEEN THE FREQUENCY OF WORD PUZZLE USE AND COGNITIVE FUNCTION IN A LARGE SAMPLE OF ADULTS AGED 50 TO 96 YEARS. Alzheimer's and Dementia, 2017, 13, P869.	0.8	0
471	[P3â€“582]: CAN INCREASING THE DIFFICULTY OF A NEUROGENESIS SENSITIVE TASK ENHANCE ITS SENSITIVITY TO DETECTING AGE RELATED DECLINES IN VOLUNTEERS AGED 50 TO 96?. Alzheimer's and Dementia, 2017, 13, P1204.	0.8	0
472	[P1â€“562]: EPIDEMIOLOGY OF PAIN IN PEOPLE WITH DEMENTIA LIVING IN CARE HOMES: LONGITUDINAL COURSE, PREVALENCE AND TREATMENT IMPLICATIONS. Alzheimer's and Dementia, 2017, 13, P509.	0.8	0
473	[P1â€“599]: ONLINE COGNITIVE TRAINING INCREASES NEUROGENESIS AND IMPROVES COGNITIVE PERFORMANCE IN ADULTS OVER 50. Alzheimer's and Dementia, 2017, 13, P525.	0.8	0
474	[P1â€“612]: THE RELATIONSHIP BETWEEN SELF REPORTED MONTHLY PHYSICAL EXERCISE FREQUENCY AND COGNITIVE FUNCTION. Alzheimer's and Dementia, 2017, 13, P531.	0.8	0
475	[P1â€“614]: THE ASSOCIATION BETWEEN COGNITIVE FUNCTION AND ACTIVITIES OF DAILY LIVING IN HEALTHY ADULTS AGED 50 AND OVER. Alzheimer's and Dementia, 2017, 13, P532.	0.8	0
476	[P2â€“204]: RPT6, 20S Î± AND Î±3 PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P684.	0.8	0
477	[P3â€“563]: RISK FACTORS FOR DEMENTIA AND COGNITIVE FUNCTION IN HEALTHY ADULTS. Alzheimer's and Dementia, 2017, 13, P1194.	0.8	0
478	[F1â€“01â€“01]: IMPACT OF WHELD INTERVENTION ON NEUROPSYCHIATRIC SYMPTOMS, ANTIPSYCHOTIC USE AND QUALITY OF LIFE IN PEOPLE WITH DEMENTIA LIVING IN NURSING HOMES: A CLUSTER RANDOMIZED TRIAL. Alzheimer's and Dementia, 2017, 13, P171.	0.8	0
479	TIME in the Context of Emerging Evidence Regarding Training Interventions for Dementia in Nursing Homes. American Journal of Geriatric Psychiatry, 2018, 26, 39-41.	1.2	0
480	P4â€“018: IMPAIRED CHRONIC PAIN LIKE BEHAVIOUR AND DISRUPTION OF OPIOIDERGIC SYSTEM IN TASTPM MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1439.	0.8	0
481	F3â€“03â€“01: EFFICACY, COST EFFECTIVENESS AND SUSTAINED ENGAGEMENT OF THE IMPROVING WELL BEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSON CENTERED CARE TRAINING PROGRAMME. Alzheimer's and Dementia, 2018, 14, P999.	0.8	0
482	P3â€“225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON DIABETIC ALZHEIMER'S PATIENTS. Alzheimer's and Dementia, 2018, 14, P1157.	0.8	0
483	P1â€“523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBI) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P532.	0.8	0
484	P2â€“010: INVOLVEMENT OF ELEVATED NEUROINFLAMMATION IN KEY REGIONS OF THE PAIN PATHWAY IN NOCICEPTIVE PROCESSING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P668.	0.8	0
485	P1â€“151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P335.	0.8	0
486	P2â€“483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER. Alzheimer's and Dementia, 2018, 14, P914.	0.8	0

#	ARTICLE	IF	CITATIONS
487	P4â€026: A TRIAGE SYSTEM FOR IDENTIFYING CANDIDATE COMPOUNDS FOR REPURPOSING AS POTENTIAL THERAPEUTICS FOR AD (GATT). <i>Alzheimer's and Dementia</i> , 2018, 14, P1443.	0.8	0
488	O3â€08â€06: RESULTS OF A PRAGMATIC, CLUSTER RANDOMISED, CONTROLLED TRIAL OF THE EFFECTIVENESS AND COSTâ€EFFECTIVENESS OF DEMENTIA CARE MAPPING (DCM) IN UK CARE HOMES (DCM EPIC TRIAL). <i>Alzheimer's and Dementia</i> , 2018, 14, P1035.	0.8	0
489	O5â€07â€05: HEALTH ECONOMIC ANALYSIS OF THE IMPROVING WELLâ€BEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSONâ€CENTRED CARE TRAINING FOR THE TREATMENT OF AGITATION IN PEOPLE WITH DEMENTIA: A CLUSTER RANDOMIZED CONTROLLED TRIAL. <i>Alzheimer's and Dementia</i> , 2018, 14, P1663.	0.8	0
490	F4â€03â€04: A SUMMARY OF THE RATIONALE AND DESIGN OF THE HARMONY STUDY: A PHASE 3 STUDY TO EVALUATE PIMAVANSERIN FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIAâ€RELATED PSYCHOSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1387.	0.8	0
491	P3â€002: PIMAVANSERIN IN ALZHEIMER'S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1062.	0.8	0
492	P2â€i43: PSYCHOSISâ€ASSOCIATED EPIGENETIC VARIATION IN PATIENTS WITH ALZHEIMER'S DISEASE ACROSS CORTICAL BRAIN REGIONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P723.	0.8	0
493	P3â€003: IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER'S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1062.	0.8	0
494	P3â€001: A RANDOMIZED, PLACEBOâ€CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P1062.	0.8	0
495	COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-2.	2.7	0
496	P4â€627: NO IMPROVEMENT IN NURSING HOME CARE FOR PEOPLE WITH DEMENTIA SINCE THE MILLENNIUM. <i>Alzheimer's and Dementia</i> , 2019, 15, P1568.	0.8	0
497	Can Intraoperative Optimization of Both Anesthetic Depth and Cerebral Oxygenation Really Result in Different Influences on Cognitive Function and Delirium in Elderly Patients Undergoing Cardiac Surgery? Response to Letter to the Editor by Xue et al.. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> . 2020, 34, 3166-3167.	1.3	0
498	Depression and anxiety are associated with decline in executive function over two years in adults 50 and over. <i>Alzheimer's and Dementia</i> , 2020, 16, e036342.	0.8	0
499	Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e039145.	0.8	0
500	Relationship between genetic risk for Alzheimer's, cognition and neuropsychiatric symptoms: A case study of DNA sampling and analysis through digital platform cohort studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e040237.	0.8	0
501	Inâ€silico high throughput whole transcriptome screening implicates cardiovascular disease and the immune system in the mechanism of action underlying adverse effects of atypical antipsychotics. <i>Alzheimer's and Dementia</i> , 2020, 16, e043586.	0.8	0
502	Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. <i>Alzheimer's and Dementia</i> , 2020, 16, e043789.	0.8	0
503	Behavioural symptoms in Alzheimerâ€™s disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism. <i>Alzheimer's and Dementia</i> , 2020, 16, e045223.	0.8	0
504	HARMONY: Response to pimavanserin in the 12â€week, openâ€label treatment phase. <i>Alzheimer's and Dementia</i> , 2020, 16, e045431.	0.8	0

#	ARTICLE	IF	CITATIONS
505	Stroke, genetic risk and incidence of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e045870.	0.8	0
506	Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects. <i>Alzheimer's and Dementia</i> , 2020, 16, e045899.	0.8	0
507	Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046004.	0.8	0
508	Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046068.	0.8	0
509	REPRINTED WITH PERMISSION OF IASP " PAIN 162 (2021) 999"1006: Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. <i>BÂ³l</i> , 2021, 22, 46-55.	0.1	0
510	Cholinergic and Serotonergic Systems in Severe Dementia. , 0, , 21-31.		0
511	Pharmacological management of neuropsychiatric symptoms in people with dementia. , 2009, , 105-116.		0
512	Pimavanserin and dementia-related psychosis. <i>Lancet Neurology</i> , The, 2022, 21, 114-115.	10.2	0
513	Repurposed Agents in Alzheimer's Disease Drug Development. , 2022, , 54-61.		0
514	Impact of brisk walking on cognitive decline in adults with and without early impairment: A FLAME analysis in the PROTECT cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
515	Development and assessment of a brief screening tool for psychosis in dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, e057766.	0.8	0
516	Repeated concussions associated with worsened working memory, attention and processing speed, but preserved delayed memory: A PROTECT study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
517	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 267-267.	2.4	0